MCID: CLR003
MIFTS: 57

Clear Cell Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 12 14
Mesonephroma 12 41 69
Water-Clear Cell Adenocarcinoma 12 69
Adenocarcinoma, Clear Cell 41 69
Mesonephroid Clear Cell Carcinoma 12
Clear Cell Adenocarcinoma Nos 12
Water-Clear Cell Carcinoma 12
Adenocarcinoma Clear Cell 51
Mesonephroma, Malignant 12
Malignant Mesonephroma 12
Wolffian Duct Neoplasm 12
Mesonephric Tumor 69
Mesonephroma Nos 12

Classifications:



Summaries for Clear Cell Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and colon, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
# Related Disease Score Top Affiliating Genes
1 urethra clear cell adenocarcinoma 33.7 AMACR KLK3 SMAD4
2 ovarian clear cell adenocarcinoma 33.6 ARID1A HNF1B SMAD3
3 urethral diverticulum 30.3 AMACR KLK3 KRT7
4 adenoma 30.2 KRT7 SMAD4 TP53
5 clear cell adenofibroma 29.9 ARID1A KRT7
6 vulva adenocarcinoma 29.8 KRT20 KRT7
7 mucinous adenocarcinoma 29.7 KRT20 KRT7 TP53
8 teratoma 29.7 KRT20 KRT7 TP53
9 transitional cell carcinoma 29.7 KRT20 KRT7 TP53
10 ovarian cancer 1 29.6 ARID1A HNF1B KRT7 TP53
11 nephrogenic adenoma 29.3 AMACR KLK3 KRT7 PAX2
12 renal cell carcinoma, nonpapillary 27.7 AMACR HNF1B KRT20 KRT7 PAX2 PTHLH
13 clear cell adenocarcinoma of the ovary 12.3
14 cervical clear cell adenocarcinoma 12.3
15 endometrial clear cell adenocarcinoma 12.3
16 fallopian tube clear cell adenocarcinoma 12.2
17 bladder clear cell adenocarcinoma 12.1
18 uterine ligament clear cell adenocarcinoma 12.1
19 ampulla of vater clear cell adenocarcinoma 12.1
20 bile duct clear cell adenocarcinoma 12.1
21 bladder tubulo-cystic clear cell adenocarcinoma 12.1
22 bladder papillary clear cell adenocarcinoma 12.1
23 bladder diffuse clear cell adenocarcinoma 12.0
24 diethylstilbestrol syndrome 11.3
25 wolffian duct adenoma 11.1
26 multilocular cystic renal neoplasm of low malignant potential 11.1
27 adenocarcinoma 11.0
28 atrophy of prostate 10.5 KLK3 TP53
29 vaginitis 10.4
30 endometriosis 10.4
31 mutyh-associated polyposis 10.4 SMAD4 TP53
32 penile disease 10.4 SMAD2 SMAD3
33 small cell neuroendocrine carcinoma 10.4 KLK3 TP53
34 prostate squamous cell carcinoma 10.4 KLK3 KRT7
35 seminal vesicle tumor 10.3 KLK3 KRT7
36 hypertrophic scars 10.3 SMAD2 SMAD3
37 malignant spiradenoma 10.3 KRT7 TP53
38 vulvar intraepithelial neoplasia 10.3 KRT7 TP53
39 female reproductive endometrioid cancer 10.3 KRT7 TP53
40 pleomorphic adenoma carcinoma 10.3 PTHLH TP53
41 rete testis adenocarcinoma 10.3 KLK3 KRT20
42 bladder carcinoma in situ 10.3 KRT7 TP53
43 hypochondrogenesis 10.3 SMAD2 SMAD3
44 nasal cavity adenocarcinoma 10.3 KRT7 TP53
45 villous adenoma 10.3 KLK3 KRT20
46 bladder papillary transitional cell neoplasm 10.3 KRT20 TP53
47 urinary tract papillary transitional cell benign neoplasm 10.3 KRT20 TP53
48 urinary tract obstruction 10.3 KLK3 SMAD2 SMAD3
49 urethritis 10.3
50 nephrogenic systemic fibrosis 10.3 SMAD2 SMAD3 SMAD4

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:



Diseases related to Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 KRT7 PAX2 PTHLH ARID1A SMAD2 TP53
2 homeostasis/metabolism MP:0005376 10.06 KRT7 AMACR PTHLH ARID1A SMAD2 HNF1B
3 cardiovascular system MP:0005385 10.05 SMAD2 PAX2 PTHLH ARID1A TP53 SMAD3
4 endocrine/exocrine gland MP:0005379 10.03 SMAD3 PAX2 PTHLH ARID1A SMAD2 HNF1B
5 embryo MP:0005380 10 SMAD3 PAX2 ARID1A SMAD2 HNF1B SMAD4
6 mortality/aging MP:0010768 9.97 PAX2 AMACR PTHLH ARID1A HNF1B SMAD2
7 craniofacial MP:0005382 9.95 SMAD3 PTHLH ARID1A SMAD2 SMAD4 TP53
8 liver/biliary system MP:0005370 9.85 SMAD3 AMACR SMAD2 HNF1B TP53 SMAD4
9 renal/urinary system MP:0005367 9.7 SMAD3 PAX2 PTHLH HNF1B KRT7 SMAD4
10 neoplasm MP:0002006 9.65 ARID1A SMAD2 TP53 SMAD3 SMAD4
11 reproductive system MP:0005389 9.5 PAX2 SMAD3 PTHLH ARID1A SMAD2 TP53
12 vision/eye MP:0005391 9.1 PAX2 PTHLH ARID1A SMAD2 TP53 SMAD3

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
6
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
10
Metformin Approved Phase 2, Phase 3 657-24-9 4091 14219
11
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
12
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
13
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
14
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
15
Maleic acid Experimental Phase 2, Phase 3 110-16-7 444266
16
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
19 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Antimetabolites Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Adjuvants, Immunologic Phase 3,Phase 1
25 Mitogens Phase 3,Phase 2,Phase 1
26 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1
30 Immunoglobulins Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
32 Antimitotic Agents Phase 3,Phase 2,Phase 1
33 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
34 Antibodies Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
36 Antiviral Agents Phase 3,Phase 2,Phase 1
37 topoisomerase I inhibitors Phase 2, Phase 3
38 Carotenoids Phase 3
39 Micronutrients Phase 3
40 Trace Elements Phase 3
41 Hypoglycemic Agents Phase 2, Phase 3
42 taxane Phase 3
43 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3, Phase 1
44
Vinblastine Approved Phase 2 865-21-4 241903 13342
45
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
46
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
49
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
50
Amifostine Approved, Investigational Phase 2 20537-88-6 2141

Interventional clinical trials:

(show top 50) (show all 94)

# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
7 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
8 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
10 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
11 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
12 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
13 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
15 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
16 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
17 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
18 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
19 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
20 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
21 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
22 Immunochemotherapy for Metastatic Renal Cell Carcinoma Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
23 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
24 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
25 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
27 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
28 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
29 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
30 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
31 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
32 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
33 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
34 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
35 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
36 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
37 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
38 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
39 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
40 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
41 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
42 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
43 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
44 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
45 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
46 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
47 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
48 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Recruiting NCT03066427 Phase 2 Sunitinib
49 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Recruiting NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
50 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Genetic Tests for Clear Cell Adenocarcinoma

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

38
Cervix, Ovary, Colon, Kidney, Lung, Prostate, Lymph Node

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 413)
# Title Authors Year
1
Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case. ( 29326971 )
2018
2
Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. ( 28689666 )
2017
3
Clear Cell Adenocarcinoma of the Urethra in Women: Distinctive MRI Findings for Differentiation From Nonadenocarcinoma and Non-Clear Cell Adenocarcinoma of the Urethra. ( 28140610 )
2017
4
Clear Cell Adenocarcinoma of the Female Urethra, Mimicking Cystocele. ( 28280687 )
2017
5
Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report. ( 28275694 )
2017
6
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )
2017
7
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
8
Clear cell adenocarcinoma of cervix in 1-year-old girl without in utero exposure to diethylstilbestrol: an uncommon tumour at an uncommon age and site. ( 28302659 )
2017
9
Clear Cell Adenocarcinoma of Female Urethra. ( 28892907 )
2017
10
A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. ( 27703378 )
2016
11
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )
2016
12
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
13
Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. ( 26807736 )
2016
14
Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. ( 27549741 )
2016
15
Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. ( 26530432 )
2015
16
Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )
2015
17
Clear cell adenocarcinoma of the urethra: review of the literature. ( 25685552 )
2015
18
Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. ( 26905123 )
2015
19
A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. ( 25642923 )
2015
20
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )
2015
21
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
22
High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. ( 26207115 )
2015
23
Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. ( 26310385 )
2015
24
Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. ( 26498012 )
2015
25
Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. ( 26109625 )
2015
26
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )
2015
27
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
28
Clear Cell Adenocarcinoma Arising in an Adenomyoma of the Broad Ligament. ( 24942896 )
2014
29
Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. ( 24690973 )
2014
30
Clear cell adenocarcinoma of the abdominal wall: a case report. ( 24937978 )
2014
31
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. ( 24815386 )
2014
32
Primary Urethral Clear-Cell Adenocarcinoma: Comprehensive Analysis by Surgical Pathology, Cytopathology, and Next-Generation Sequencing. ( 24389164 )
2014
33
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. ( 24721826 )
2014
34
Clear cell adenocarcinoma of the colon: a case report and review of the literature. ( 24716050 )
2014
35
Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. ( 24817975 )
2014
36
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. ( 24669262 )
2014
37
Primary clear cell adenocarcinoma of the peritoneum presents as Sister Mary Joseph's nodule: a case report and literature review. ( 25556287 )
2014
38
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
39
Immunohistochemical and molecular features of primary clear cell-adenocarcinoma of the rectum, as predictive factors for individualized therapy. ( 25178336 )
2014
40
Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. ( 25301100 )
2014
41
Clear Cell Adenocarcinoma of the Prostate: A Rare Oncologic Entity in a 42-Year-Old African American Man. ( 25217452 )
2014
42
Primary clear cell adenocarcinoma of the colon presenting as a huge extracolic mass: A case report. ( 25202428 )
2014
43
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. ( 24504419 )
2014
44
A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. ( 25460452 )
2014
45
Clear Cell Adenocarcinoma of the Urethra: 18F-FDG PET/CT Imaging. ( 25140553 )
2014
46
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
47
Cervical clear cell adenocarcinoma infected with human papillomavirus type 18 in an adolescent. ( 23849091 )
2014
48
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. ( 25275661 )
2014
49
Clear cell adenocarcinoma of the peritoneum: a case report and literature review. ( 25366349 )
2014
50
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. ( 24987918 )
2014

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 218693 7 116312458 116438439 Amplification MET Clear cell adenocarcinoma
2 266962 Y 174481503 174538309 Duplication AZF Clear cell adenocarcinoma

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 HNF1B KRT20 KRT7 SMAD2 SMAD3 SMAD4
2
Show member pathways
12.95 KLK3 SMAD2 SMAD3 SMAD4 TP53
3
Show member pathways
12.72 SMAD2 SMAD3 SMAD4 TP53
4 12.7 KLK3 SMAD2 SMAD3 SMAD4 TP53
5
Show member pathways
12.57 ARID1A SMAD2 SMAD3 SMAD4 TP53
6
Show member pathways
12.38 HNF1B SMAD2 SMAD3 SMAD4
7 12.32 SMAD2 SMAD3 SMAD4 TP53
8 12.24 SMAD2 SMAD3 SMAD4 TP53
9
Show member pathways
12.22 SMAD2 SMAD3 SMAD4 TP53
10
Show member pathways
12.12 SMAD2 SMAD3 SMAD4
11 12.07 SMAD2 SMAD3 TP53
12 12.06 PAX2 SMAD2 SMAD3 SMAD4
13 12.05 SMAD2 SMAD3 SMAD4
14 12.05 SMAD2 SMAD4 TP53
15
Show member pathways
12.04 HNF1B PTHLH SMAD2 SMAD3 SMAD4
16 12 SMAD2 SMAD3 SMAD4
17
Show member pathways
11.99 SMAD2 SMAD3 SMAD4
18 11.99 SMAD2 SMAD3 SMAD4
19 11.95 SMAD2 SMAD3 SMAD4 TP53
20 11.91 SMAD3 SMAD4 TP53
21
Show member pathways
11.89 SMAD2 SMAD3 SMAD4 TP53
22 11.86 SMAD3 SMAD4 TP53
23 11.84 SMAD2 SMAD3 SMAD4 TP53
24 11.83 SMAD2 SMAD3 SMAD4
25 11.81 SMAD2 SMAD3 SMAD4
26
Show member pathways
11.8 SMAD2 SMAD3 SMAD4
27 11.79 SMAD2 SMAD3 SMAD4 TP53
28 11.78 KLK3 SMAD3 SMAD4
29
Show member pathways
11.78 SMAD2 SMAD3 SMAD4
30 11.74 SMAD2 SMAD3 SMAD4
31 11.71 SMAD3 SMAD4 TP53
32
Show member pathways
11.69 SMAD2 SMAD3 SMAD4
33 11.68 SMAD2 SMAD3 SMAD4
34 11.64 SMAD2 SMAD3 SMAD4
35 11.63 SMAD2 SMAD3 SMAD4
36
Show member pathways
11.61 SMAD2 SMAD3 SMAD4
37
Show member pathways
11.54 SMAD2 SMAD3 SMAD4
38 11.5 SMAD2 SMAD3 SMAD4
39 11.43 SMAD3 SMAD4 TP53
40 11.42 SMAD2 SMAD3 SMAD4
41
Show member pathways
11.4 SMAD2 SMAD3 SMAD4
42 11.32 SMAD2 SMAD3 TP53
43 11.01 SMAD3 SMAD4
44 10.97 SMAD2 SMAD3 SMAD4
45 10.83 SMAD2 SMAD3 SMAD4
46 10.41 SMAD2 SMAD3 SMAD4
47 10.05 SMAD2 SMAD3 SMAD4

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.77 KLK3 PAX2 SMAD2 SMAD3 TP53
2 nuclear chromatin GO:0000790 9.55 ARID1A SMAD2 SMAD3 SMAD4 TP53
3 transcription factor complex GO:0005667 9.35 HNF1B SMAD2 SMAD3 SMAD4 TP53
4 activin responsive factor complex GO:0032444 9.32 SMAD2 SMAD4
5 heteromeric SMAD protein complex GO:0071144 9.26 SMAD2 SMAD3
6 SMAD protein complex GO:0071141 8.8 SMAD2 SMAD3 SMAD4
7 nucleus GO:0005634 10.1 ARID1A HNF1B KLK3 KRT7 PAX2 PTHLH

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 HNF1B PAX2 SMAD3 TP53
2 positive regulation of gene expression GO:0010628 9.94 HNF1B SMAD2 SMAD3 TP53
3 negative regulation of transcription by RNA polymerase II GO:0000122 9.93 ARID1A HNF1B SMAD2 SMAD3 SMAD4 TP53
4 negative regulation of cell proliferation GO:0008285 9.91 PTHLH SMAD2 SMAD3 SMAD4 TP53
5 protein deubiquitination GO:0016579 9.88 SMAD2 SMAD3 SMAD4 TP53
6 negative regulation of cell growth GO:0030308 9.81 SMAD3 SMAD4 TP53
7 anterior/posterior pattern specification GO:0009952 9.8 HNF1B SMAD2 SMAD4
8 positive regulation of transcription, DNA-templated GO:0045893 9.8 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
9 transforming growth factor beta receptor signaling pathway GO:0007179 9.79 SMAD2 SMAD3 SMAD4
10 wound healing GO:0042060 9.79 SMAD2 SMAD3 TP53
11 SMAD protein signal transduction GO:0060395 9.72 SMAD2 SMAD3 SMAD4
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.7 SMAD2 SMAD3 SMAD4
13 embryonic pattern specification GO:0009880 9.66 SMAD2 SMAD3
14 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.66 SMAD3 TP53
15 signal transduction involved in regulation of gene expression GO:0023019 9.65 SMAD2 SMAD3
16 osteoblast development GO:0002076 9.65 PTHLH SMAD3
17 activin receptor signaling pathway GO:0032924 9.64 SMAD2 SMAD3
18 positive regulation of SMAD protein import into nucleus GO:0060391 9.63 SMAD3 SMAD4
19 primary miRNA processing GO:0031053 9.61 SMAD2 SMAD3
20 embryonic foregut morphogenesis GO:0048617 9.6 SMAD2 SMAD3
21 pericardium development GO:0060039 9.59 SMAD2 SMAD3
22 developmental growth GO:0048589 9.58 SMAD2 SMAD3 SMAD4
23 nodal signaling pathway GO:0038092 9.57 SMAD2 SMAD3
24 pronephros development GO:0048793 9.56 HNF1B PAX2
25 regulation of transforming growth factor beta2 production GO:0032909 9.54 SMAD3 SMAD4
26 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.54 SMAD2 SMAD3 SMAD4
27 SMAD protein complex assembly GO:0007183 9.5 SMAD2 SMAD3 SMAD4
28 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.49 HNF1B PAX2
29 nephric duct formation GO:0072179 9.48 HNF1B PAX2
30 gastrulation GO:0007369 9.46 ARID1A SMAD2 SMAD3 SMAD4
31 paraxial mesoderm morphogenesis GO:0048340 9.43 SMAD2 SMAD3
32 endoderm development GO:0007492 9.26 HNF1B SMAD2 SMAD3 SMAD4
33 regulation of binding GO:0051098 8.8 SMAD2 SMAD3 SMAD4
34 regulation of transcription, DNA-templated GO:0006355 10.21 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
35 transcription, DNA-templated GO:0006351 10.2 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
36 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 HNF1B PAX2 SMAD2 SMAD3 SMAD4 TP53

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 DNA binding transcription factor activity GO:0003700 9.95 HNF1B SMAD2 SMAD3 SMAD4 TP53
2 chromatin binding GO:0003682 9.84 SMAD2 SMAD3 SMAD4 TP53
3 protein heterodimerization activity GO:0046982 9.8 HNF1B SMAD2 SMAD3 SMAD4 TP53
4 transcription factor binding GO:0008134 9.76 PAX2 SMAD2 SMAD3 TP53
5 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.67 HNF1B SMAD3 SMAD4 TP53
6 enhancer binding GO:0035326 9.51 SMAD2 SMAD3
7 co-SMAD binding GO:0070410 9.49 SMAD2 SMAD3
8 I-SMAD binding GO:0070411 9.48 SMAD2 SMAD4
9 primary miRNA binding GO:0070878 9.43 SMAD2 SMAD3
10 transcription regulatory region DNA binding GO:0044212 9.35 HNF1B PAX2 SMAD3 SMAD4 TP53
11 R-SMAD binding GO:0070412 9.33 SMAD2 SMAD3 SMAD4
12 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.32 SMAD2 SMAD3
13 transcription factor activity, protein binding GO:0000988 9.26 SMAD3 SMAD4
14 proximal promoter sequence-specific DNA binding GO:0000987 8.92 HNF1B PAX2 SMAD3 SMAD4
15 DNA binding GO:0003677 10.07 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4

Sources for Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....